Innovotech
Specializing in biofilm product research and development.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $300k | Grant | |
| Total Funding | 000k | ||
| CAD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (17 %) | 19 % | 21 % | 24 % | (24 %) | 5 % | 86 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (13 %) | (1 %) | 10 % | 24 % | (2 %) | (24 %) | 5 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (15 %) | (5 %) | 9 % | 25 % | (12 %) | (13 %) | 10 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 5 % | 2 % | 4 % | 2 % | 10 % | 16 % | 13 % |
Source: Company filings or news article
Related Content
Innovotech is a pioneering company specializing in antimicrobial solutions, particularly targeting chronic, recurrent, and medical device-related infections caused by biofilms. The company operates in the healthcare and agricultural sectors, offering a range of products and services designed to combat microbial threats. Innovotech's core offerings include antimicrobial silver compounds, which are highly effective agents suited for coating or incorporation into medical devices. Additionally, the company provides contract research services, developing custom protocols and testing procedures based on the MBEC system, a method for evaluating biofilm susceptibility to antimicrobials.
Innovotech serves a diverse clientele, including medical device manufacturers, healthcare providers, and agricultural businesses. The company operates on a B2B (business-to-business) model, generating revenue through the sale of its antimicrobial products and contract research services. Innovotech's business model focuses on providing tailored solutions to meet the specific needs of its clients, ensuring high efficacy and safety standards.
The market Innovotech operates in is characterized by a growing demand for effective antimicrobial solutions, driven by the increasing prevalence of biofilm-related infections and the need for safer agricultural practices. The company's innovative approach and commitment to research and development position it as a leader in this niche market.
Keywords: antimicrobial solutions, biofilm, medical devices, agricultural applications, custom protocols, MBEC system, high throughput screening, contract research, silver compounds, infection control.